Payers point to Spark’s gene therapy as a model for innovative pricing plans

12th January 2018 Uncategorised 0

When Spark Therapeutics announced an $850,000 price for its gene therapy Luxturna last week, some critics held it up as the latest example of an expensive new treatment that could break the bank for the healthcare system. But at the J.P. Morgan Healthcare conference this week, it was clear that sentiment is rapidly changing.

More: Payers point to Spark’s gene therapy as a model for innovative pricing plans
Source: fierce